Dec 31, 2010 by Brian Orelli, PhDCEL-SCI Investors Cheer a Bit Too LoudlyFinally, a phase 3 trial for cancer therapy Multikine.
Dec 30, 2010 by Brian Orelli, PhDThe Best Stocks for 2011: DendreonThe risk-reward profile is looking mighty nice.
Dec 30, 2010 by Brian Orelli, PhDPfizer Diagnoses Fido, TooThe drugmaker's animal health division purchases Synbiotics.
Dec 30, 2010 by Brian Orelli, PhDThat's What You Call Product Differentiation?Endo Pharma misses the mark.
Dec 29, 2010 by Brian Orelli, PhDThe Painful Death of a Promising Drug ClassMore clinical holds for anti-nerve growth factor drugs.
Dec 28, 2010 by Brian Orelli, PhDNo Guts, No GloryFor better or worse, Elan gains full control of ELND005.
Dec 28, 2010 by Brian Orelli, PhDDouble-Digit Increase! Haven't We Learned Anything?MannKind's investors need a history lesson.
Dec 27, 2010 by Brian Orelli, PhDFDA Kicks Dust on Alimera's Fairy TaleEight months after its IPO, Alimera gets hammered.
Dec 27, 2010 by Brian Orelli, PhDPainful Clinical Hold? Not Really.Regeneron offers the benefits of a full pipeline.
Dec 23, 2010 by Brian Orelli, PhDCorcept May Have Hit Pay DirtCorcept's Corlux tackles Cushing's syndrome.
Dec 23, 2010 by Brian Orelli, PhDSo Does This Drug Work or Not?Another arm of Vertex's VX-222 study fails, but there are still three left.
Dec 22, 2010 by Brian Orelli, PhDWill the FDA Be Kind to MannKind?Decision on inhaled insulin product Afrezza is due by Dec. 29.
Dec 21, 2010 by Brian Orelli, PhD4 Drugmakers, 5 Deals, Christmas Is HereFor their partners, that is.
Dec 20, 2010 by Brian Orelli, PhDA Good Fit. On the Surface.Digging a little deeper into Gilead's acquisition of Arresto.
Dec 17, 2010 by Brian Orelli, PhDAn Overnight Double: Santa Visits InterMune in EuropeThe U.S. still offers a lump of coal.
